Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ATI-2138
- Development stage
- Phase 2
- Lead developer
- Aclaris Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ATI-2138 is a novel investigational oral small molecule covalent inhibitor developed by Aclaris Therapeutics. It acts as a dual inhibitor of interleukin-2-inducible T cell kinase (ITK), resting lymphocyte kinase, and Janus kinase 3 (JAK3). The drug demonstrates high potency and selectivity for both ITK and JAK3, with minimal activity against other related kinases. In preclinical studies, ATI-2138 showed disease-modifying activity in rodent models of arthritis and colitis. Early clinical trials in healthy human participants indicated that the drug is well tolerated with linear pharmacokinetics and dose-dependent inhibition of biomarkers linked to ITK and JAK3 activity. Its unique dual mechanism targets key inflammatory signaling pathways implicated in autoimmune and chronic inflammatory diseases.
02
Targets
Beyond the preview
Go deeper on ATI-2138.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ATI-2138.